Advanced Search

Study Preview



Study Title and Description

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.



Key Questions Addressed
2 Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Author Barrett-Connor E., Cauley JA., Kulkarni PM., Sashegyi A., Cox DA., Geiger MJ.
Country Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California 92093-0607, USA. ebarrettconnor@ucsd.edu
Year 2004
Numbers Pubmed ID: 15231013

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.